Trial Profile

Adaptive Phase I-II Clinical Trial of Preventive Vaccine Consisting of Autologous Dendritic Cells Previously Incubated With S-protein From Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), in Subjects Negative for COVID-19 Infection and Anti-SARS-CoV-2 Antibodies

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I/II

Latest Information Update: 08 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AV-COVID-19 (Primary) ; Granulocyte macrophage colony stimulating factor
Indications COVID 2019 infections
Focus Adverse reactions
Sponsors AiVita Biomedical

01 May 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
14 Dec 2021 Planned End Date changed from 1 Jan 2023 to 1 Jan 2024.
14 Dec 2021 Planned primary completion date changed from 1 Jun 2022 to 1 Jun 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com